Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressmen Seek GAO Input On FDA’s Failure To Discipline Clinical Trial Investigators

This article was originally published in The Pink Sheet Daily

Executive Summary

Request would bring government watchdog agency into investigation of integrity of drug approval process.

You may also be interested in...



FDA Cannot Escape Congressional Crosshairs

House Republicans question Commissioner von Eschenbach on whether Office of Criminal Investigations is the best use of limited resources.

FDA Cannot Escape Congressional Crosshairs

House Republicans question Commissioner von Eschenbach on whether Office of Criminal Investigations is the best use of limited resources.

NDAs Supported By Foreign Data To Be Reviewed By HHS Inspector General

HHS' Office of Inspector General will examine how FDA handles the growing number of clinical trials being conducted overseas

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel